Earth Science Tech, Inc. (OTC PINK: ETST) Announced 5 New Products Under Development in Joint Venture
Earth Science Tech, Inc. (OTC PINK: ETST) recently announced the commencement of patent studies on three nutraceutical products, as well as composition work on two new cannabinoid-based pharmaceutical drugs. This is the first initiative in the works as a result of the joint venture that was finalized earlier this month between the company’s wholly-owned subsidiary, Cannabis Therapeutics, and Smart Medicines GMP.
ETST’s new treatment options are expected to be finished and launched over the next year and a half, with the pharmaceuticals expected to launch in the second quarter of 2018. Cannabis Therapeutics’ line of Cannabinoid-Based nutraceutical products seeks to provide a variety of health and wellness benefits to consumers; from strengthening the immune system to improving and protecting brain and liver function, there will be treatments for many bodily needs. The final nutraceutical product being developed even plans to reduce occurrence rates of cancer and prevent some of the more common causes.
Once work is finished on the nutraceutical products, the company plans to begin work on prescription depression, anxiety, and PTSD treatment followed by development of a pharmaceutical-grade cancer treatment. Both products will use a combination of generic drugs, CBD hemp oil, and pure natural molecules. ETST’s goal is to provide patients with the unique health benefits of CBD treatment, with the backing of tested and proven cancer and mental illness treatments.
Smart Medicines will focus heavily on the research and development with its state-of-the-art laboratory and research facilities that feature high tech equipment and botanical extraction units, as per ETST’s joint venture release with Smart Medicines GMP. CEO of Earth Science Tech, Inc., Dr. Michel Aubé said. “We are very excited to be making such big strides in our relationship with Smart Medicines GMP after such a short time,” adding, “We are building products that we feel could find mass-market acceptance, as they will leverage the well-documented strengths of several existing drugs.”